Hydroxocobalamin as the Preferred Form of Vitamin B12 Replacement

Preferred Form and General Recommendations

• Hydroxocobalamin should be used as the preferred formulation for vitamin B12 replacement, especially in individuals presenting with neurological symptoms or renal impairment, while cyanocobalamin is generally avoided in these populations. 1

Neurological Involvement

• For patients with vitamin B12 deficiency manifesting neurological signs (e.g., sensory disturbances, gait instability, visual or cognitive changes), initiate intramuscular hydroxocobalamin 1 mg on alternate days and continue until clinical improvement plateaus; the treatment duration is not fixed and may extend for weeks to months. 1
• Treatment must begin immediately without waiting for specialist referral; prompt initiation of hydroxocobalamin is essential. 1
• After starting therapy, arrange urgent consultation with neurology and hematology services. 1
• Folic acid supplementation must not be given before correcting the vitamin B12 deficiency, as it can mask the deficiency and precipitate subacute combined degeneration of the spinal cord. 1

Non‑Neurological Deficiency

• In the absence of neurological manifestations, administer a loading regimen of hydroxocobalamin 1 mg intramuscularly three times per week for two weeks. 1
• Follow the loading phase with lifelong maintenance dosing of hydroxocobalamin 1 mg intramuscularly every 2–3 months. 1

Renal Impairment Considerations

• Cyanocobalamin is contraindicated or should be avoided in patients with renal impairment because its cyanide moiety is metabolized to thiocyanate, which accumulates when kidney function is reduced. 2
• In individuals with an estimated glomerular filtration rate below 50 mL/min/1.73 m², cyanocobalamin use has been linked to increased adverse events and overall harm. 2
• Methylcobalamin or hydroxocobalamin are preferred alternatives for renal‑impaired patients, as they do not generate thiocyanate during metabolism. 2
• Both cyanocobalamin and hydroxocobalamin lower plasma total homocysteine by roughly one‑third in patients with end‑stage renal disease, but the superior safety profile of hydroxocobalamin supports its use in this group. 2

Diagnostic and Monitoring Recommendations

• Serum vitamin B12 measurement alone is insufficient for diagnosis; clinicians should employ active B12 (holotranscobalamin) or functional biomarkers such as methylmalonic acid or homocysteine to detect metabolic deficiency, which affects an estimated 10–40 % of the population. 3

Oral Therapy and Malabsorption

• Oral vitamin B12 supplementation should not replace intramuscular therapy in conditions causing malabsorption (e.g., pernicious anemia, post‑bariatric surgery, or significant gastrointestinal disease). Intramuscular hydroxocobalamin remains the standard of care. 1

Guidelines for Management of Severe Vitamin B12 Deficiency

Assessment of Neurological Involvement

• Screen patients with severe vitamin B12 deficiency for neurological manifestations—including unexplained sensory symptoms (e.g., pins‑and‑needles), motor and gait disturbances, balance problems leading to falls, sensory ataxia, and visual disturbances related to optic nerve dysfunction—before initiating therapy. 4, 5

Immediate Treatment Imperatives

• Initiate intramuscular hydroxocobalamin promptly in all cases of severe deficiency; the specific regimen should be tailored according to the presence or absence of neurological involvement. 4
• Do not administer folic acid prior to correcting vitamin B12 deficiency, as folic acid can mask the deficiency and precipitate subacute combined degeneration of the spinal cord. 4, 5
• Do not postpone treatment while awaiting specialist consultation; begin intramuscular hydroxocobalamin immediately when neurological symptoms are present. 4

Specialist Consultation for Neurological Cases

• When neurological involvement is identified, obtain urgent consultation from both a neurologist and a haematologist. 4

Loading Phase for Neurological Involvement

• Administer hydroxocobalamin 1 mg intramuscularly on alternate days and continue until no further clinical improvement is observed (the duration is not fixed). 6

Long‑Term Maintenance

• Maintain lifelong intramuscular hydroxocobalamin therapy regardless of symptom resolution; the injection schedule should be individualized based on recurrence of symptoms rather than solely on laboratory values. 4, 6